


# Author's Accepted Manuscript

Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action

Sharmistha Bhattacharyya, Subhashis Pal,  
Naibedy Chattopadhyay



PII: S0014-2999(18)30106-7  
DOI: <https://doi.org/10.1016/j.ejphar.2018.02.028>  
Reference: EJP71681

To appear in: *European Journal of Pharmacology*

Received date: 9 November 2017  
Revised date: 15 February 2018  
Accepted date: 19 February 2018

Cite this article as: Sharmistha Bhattacharyya, Subhashis Pal and Naibedy Chattopadhyay, Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.02.028>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: a critical assessment of the mechanism of action

Sharmistha Bhattacharyya<sup>1,2</sup>, Subhashis Pal<sup>1</sup>, Naibedya Chattopadhyay<sup>1,3\*</sup>

<sup>1</sup>Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow 226021, India

<sup>2</sup>Women Scientist, DBT-BIO-Care, Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow 226021, India

<sup>3</sup>AcSIR, CSIR-Central Drug Research Institute Campus, Lucknow 226021, India.

\* **Corresponding author.** Naibedya Chattopadhyay, PhD, Endocrinology Division, CSIR-Central Drug Research Institute, Lucknow 226021, India. Tel.: +91-522 2613894; fax: +91-522 2623938. n\_chattopadhyay@cdri.res.in.

### Abstract

Promising news in the treatment of osteoporosis is that sequestering sclerostin from circulation with antibodies stimulates robust bone formation. Pre-clinical studies on rodents and monkeys have confirmed that treatment with anti-sclerostin monoclonal antibody (Scl-Ab) increases bone mass improves bone strength and enhances fracture repair. Clinical trials show that bone gain (anabolic effect) is transient and are primarily at central (spine and hips) than peripheral (wrist) sites. Interestingly Scl-Ab also inhibited bone resorption. Thus Scl-Ab is being regarded as the pharmacologic agent with dual properties - stimulating bone formation and decreasing bone resorption. Sclerostin neutralization transiently increases bone formation markers in post-menopausal women and like parathyroid hormone (PTH) activates osteoblasts and lining cells resulting in bone anabolic effect. However, unlike PTH, sclerostin antibody also decreases bone resorption (anti-catabolic). Although, the U.S. Food and Drug Administration have accepted the

Download English Version:

<https://daneshyari.com/en/article/8529190>

Download Persian Version:

<https://daneshyari.com/article/8529190>

[Daneshyari.com](https://daneshyari.com)